Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs

Washington Drug Letter
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00